Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 6/20 | 0.55 |
| ▸ | LMNA | P02545 | 4/20 | 0.55 |
| ▸ | ADRA2B | P18089 | 3/20 | 0.55 |
| ▸ | ADRA2C | P18825 | 3/20 | 0.55 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.55 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.55 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.55 |
| ▸ | NISCH | Q9Y2I1 | 2/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.55 |
| ▸ | SLC22A3 | O75751 | 1/20 | 0.55 |
| ▸ | HTR1A | P08908 | 1/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.55 |
| ▸ | HRH2 | P25021 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.55 |
| ▸ | SLC47A1 | Q96FL8 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20246637 | 0.90 | LMNA (0.44) | ADRA2ALMNAADRA2BADRA2CADRA1D | |
| SCHEMBL560777 | 0.88 | LMNA (0.56) | ADRA2ALMNAADRA2BADRA2CADRA1D | |
| Iodide SCHEMBL16227866 | 0.87 | LMNA (0.59) | ADRA2ALMNAADRA2BADRA2CADRA1D | |
| SCHEMBL8148008 | 0.86 | LMNA (0.52) | ADRA2ALMNAADRA2BADRA2CADRA1D | |
| SCHEMBL560745 | 0.86 | LMNA (0.55) | ADRA2ALMNAADRA2BADRA2CADRA1D | |
| SCHEMBL8133648 | 0.86 | ADRA2A (0.52) | ADRA2ALMNAADRA2BADRA2CADRA1D | |
| SCHEMBL20017860 | 0.86 | SMN1; SMN2 (0.50) | ADRA2ALMNAADRA2BADRA2CADRA1D | |
| SCHEMBL561403 | 0.86 | LMNA (0.62) | ADRA2ALMNAADRA2BADRA2CADRA1D | |
| SCHEMBL8133645 | 0.86 | SMN1; SMN2 (0.50) | ADRA2ALMNAADRA2BADRA2CADRA1D | |
| SCHEMBL8139996 | 0.86 | HTR1D (0.52) | ADRA2ALMNAADRA2BADRA2CADRA1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 102 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230062049-A1 | METHODS OF TREATING ALPHA ADRENERGIC MEDIATED CONDITIONS | ALLERGAN, INC. | 2023-03-02 | — | — | US | claimed |
| US-20200330428-A1 | METHODS OF TREATING ALPHA ADRENERGIC MEDIATED CONDITIONS | ALLERGAN INC (US) | 2020-10-22 | — | — | US | claimed |
| US-20180344692-A1 | METHODS OF TREATING ALPHA ADRENERGIC MEDIATED CONDITIONS | ALLERGAN INC (US) | 2018-12-06 | — | — | US | claimed |
| EP-2303264-B1 | METHODS OF TREATING ALPHA ADRENERGIC MEDIATED CONDITIONS USING IMIDAZOLINE DERIVATIVES | ALLERGAN INC (US) | 2018-04-04 | — | — | EP | claimed |
| US-20180071260-A1 | METHODS OF TREATING ALPHA ADRENERGIC MEDIATED CONDITIONS | ALLERGAN, INC. | 2018-03-15 | — | — | US | claimed |
| EP-2932968-B1 | COMPOUND FOR TREATING ALPHA ADRENERGIC MEDIATED CONDITIONS | ALLERGAN INC (US) | 2018-01-17 | — | — | EP | claimed |
| US-9849113-B2 | Methods of treating α adrenergic mediated conditions | ALLERGAN, INC. (US) | 2017-12-26 | — | — | US | claimed |
| US-20170172982-A1 | METHODS OF TREATING ALPHA ADRENERGIC MEDIATED CONDITIONS | ALLERGAN, INC. | 2017-06-22 | — | — | US | claimed |
| US-9623006-B2 | Methods of treating α adrenergic mediated conditions | ALLERGAN, INC. (US) | 2017-04-18 | — | — | US | claimed |
| EP-2932968-A1 | COMPOUND FOR TREATING ALPHA ADRENERGIC MEDIATED CONDITIONS | ALLERGAN, INC. (US) | 2015-10-21 | — | — | EP | claimed |
| US-20150224080-A1 | METHODS OF TREATING ALPHA ADRENERGIC MEDIATED CONDITIONS | ALLERGAN, INC. | 2015-08-13 | — | — | US | claimed |
| US-9034910-B2 | Methods of treating alpha adrenergic mediated conditions | ALLERGAN, INC. (US) | 2015-05-19 | — | — | US | claimed |
| US-20120165380-A1 | METHODS OF TREATING ALPHA ADRENERGIC MEDIATED CONDITIONS | ALLERGAN, INC. (US) | 2012-06-28 | — | — | US | claimed |
| US-20120035235-A1 | METHODS OF TREATING ALPHA ADRENERGIC MEDIATED CONDITIONS | ALLERGAN, INC. (US) | 2012-02-09 | — | — | US | claimed |
| US-8071636-B2 | Methods of treating alpha adrenergic mediated conditions | ALLERGAN, INC. (US) | 2011-12-06 | — | — | US | claimed |
| EP-2377534-A1 | Methods of treating alpha adrenergic mediated conditions | ALLERGAN, INC. (US) | 2011-10-19 | — | — | EP | claimed |
| EP-2303264-A1 | METHODS OF TREATING ALPHA ADRENERGIC MEDIATED CONDITIONS | Allergan, Inc. (US) | 2011-04-06 | — | — | EP | claimed |
| WO-2009152052-A1 | METHODS OF TREATING ALPHA ADRENERGIC MEDIATED CONDITIONS | ALLERGAN, INC. (US) | 2009-12-17 | — | — | WO | claimed |
| US-20090306161-A1 | METHODS OF TREATING ALPHA ADRENERGIC MEDIATED CONDITIONS | ALLERGAN, INC. (US) | 2009-12-10 | — | — | US | claimed |
| US-20230062049-A1 | METHODS OF TREATING ALPHA ADRENERGIC MEDIATED CONDITIONS | ALLERGAN, INC. | 2023-03-02 | — | — | US | disclosed |
| US-20230062049-A1 | METHODS OF TREATING ALPHA ADRENERGIC MEDIATED CONDITIONS | ALLERGAN, INC. | 2023-03-02 | — | — | US | disclosed |
| US-20200330428-A1 | METHODS OF TREATING ALPHA ADRENERGIC MEDIATED CONDITIONS | ALLERGAN INC (US) | 2020-10-22 | — | — | US | disclosed |
| US-20200330428-A1 | METHODS OF TREATING ALPHA ADRENERGIC MEDIATED CONDITIONS | ALLERGAN INC (US) | 2020-10-22 | — | — | US | disclosed |
| US-10251865-B2 | Method of activating regulatory T cells with alpha-2B adrenergic receptor agonists | ALLERGAN, INC. (US) | 2019-04-09 | — | — | US | disclosed |
| US-20180344692-A1 | METHODS OF TREATING ALPHA ADRENERGIC MEDIATED CONDITIONS | ALLERGAN INC (US) | 2018-12-06 | — | — | US | disclosed |
| EP-3332782-A1 | METHOD OF ACTIVATING REGULATORY T CELLS WITH ALPHA-2B ADRENERGIC RECEPTOR AGONISTS | ALLERGAN, INC. (US) | 2018-06-13 | — | — | EP | disclosed |
| EP-2303264-B1 | METHODS OF TREATING ALPHA ADRENERGIC MEDIATED CONDITIONS USING IMIDAZOLINE DERIVATIVES | ALLERGAN INC (US) | 2018-04-04 | — | — | EP | disclosed |
| EP-2303264-B1 | METHODS OF TREATING ALPHA ADRENERGIC MEDIATED CONDITIONS USING IMIDAZOLINE DERIVATIVES | ALLERGAN INC (US) | 2018-04-04 | — | — | EP | disclosed |
| EP-2605771-B1 | METHOD OF ACTIVATING REGULATORY T CELLS WITH ALPHA-2B ADRENERGIC RECEPTOR AGONISTS | ALLERGAN INC (US) | 2018-04-04 | — | — | EP | disclosed |
| US-20180071260-A1 | METHODS OF TREATING ALPHA ADRENERGIC MEDIATED CONDITIONS | ALLERGAN, INC. | 2018-03-15 | — | — | US | disclosed |
| US-20180071259-A1 | METHOD OF ACTIVATING REGULATORY T CELLS WITH ALPHA-2B ADRENERGIC RECEPTOR AGONISTS | ALLERGAN, INC. | 2018-03-15 | — | — | US | disclosed |
| US-20180071260-A1 | METHODS OF TREATING ALPHA ADRENERGIC MEDIATED CONDITIONS | ALLERGAN, INC. | 2018-03-15 | — | — | US | disclosed |
| US-20180071260-A1 | METHODS OF TREATING ALPHA ADRENERGIC MEDIATED CONDITIONS | ALLERGAN, INC. | 2018-03-15 | — | — | US | disclosed |
| US-20180071259-A1 | METHOD OF ACTIVATING REGULATORY T CELLS WITH ALPHA-2B ADRENERGIC RECEPTOR AGONISTS | ALLERGAN, INC. | 2018-03-15 | — | — | US | disclosed |
| EP-2932968-B1 | COMPOUND FOR TREATING ALPHA ADRENERGIC MEDIATED CONDITIONS | ALLERGAN INC (US) | 2018-01-17 | — | — | EP | disclosed |
| EP-2932968-B1 | COMPOUND FOR TREATING ALPHA ADRENERGIC MEDIATED CONDITIONS | ALLERGAN INC (US) | 2018-01-17 | — | — | EP | disclosed |
| US-9849113-B2 | Methods of treating α adrenergic mediated conditions | ALLERGAN, INC. (US) | 2017-12-26 | — | — | US | disclosed |
| US-9849113-B2 | Methods of treating α adrenergic mediated conditions | ALLERGAN, INC. (US) | 2017-12-26 | — | — | US | disclosed |
| US-9849113-B2 | Methods of treating α adrenergic mediated conditions | ALLERGAN, INC. (US) | 2017-12-26 | — | — | US | disclosed |
| US-20170172982-A1 | METHODS OF TREATING ALPHA ADRENERGIC MEDIATED CONDITIONS | ALLERGAN, INC. | 2017-06-22 | — | — | US | disclosed |
| US-20170172982-A1 | METHODS OF TREATING ALPHA ADRENERGIC MEDIATED CONDITIONS | ALLERGAN, INC. | 2017-06-22 | — | — | US | disclosed |
| US-20170172982-A1 | METHODS OF TREATING ALPHA ADRENERGIC MEDIATED CONDITIONS | ALLERGAN, INC. | 2017-06-22 | — | — | US | disclosed |
| US-9623006-B2 | Methods of treating α adrenergic mediated conditions | ALLERGAN, INC. (US) | 2017-04-18 | — | — | US | disclosed |
| US-9623006-B2 | Methods of treating α adrenergic mediated conditions | ALLERGAN, INC. (US) | 2017-04-18 | — | — | US | disclosed |
| US-9623006-B2 | Methods of treating α adrenergic mediated conditions | ALLERGAN, INC. (US) | 2017-04-18 | — | — | US | disclosed |
| US-20170079956-A1 | METHOD OF ACTIVATING REGULATORY T CELLS WITH ALPHA-2B ADRENERGIC RECEPTOR AGONISTS | ALLERGAN, INC. | 2017-03-23 | — | — | US | disclosed |
| US-20170079956-A1 | METHOD OF ACTIVATING REGULATORY T CELLS WITH ALPHA-2B ADRENERGIC RECEPTOR AGONISTS | ALLERGAN, INC. | 2017-03-23 | — | — | US | disclosed |
| US-9545394-B2 | Method of activating regulatory T cells with alpha-2B adrenergic receptor agonists | ALLERGAN, INC. (US) | 2017-01-17 | — | — | US | disclosed |
| US-9545394-B2 | Method of activating regulatory T cells with alpha-2B adrenergic receptor agonists | ALLERGAN, INC. (US) | 2017-01-17 | — | — | US | disclosed |
| US-20160158199-A1 | METHOD OF ACTIVATING REGULATORY T CELLS WITH ALPHA-2B ADRENERGIC RECEPTOR AGONISTS | ALLERGAN, INC. | 2016-06-09 | — | — | US | disclosed |
| US-20160158199-A1 | METHOD OF ACTIVATING REGULATORY T CELLS WITH ALPHA-2B ADRENERGIC RECEPTOR AGONISTS | ALLERGAN, INC. | 2016-06-09 | — | — | US | disclosed |
| US-9289420-B2 | Method of activating regulatory T cells with alpha-2B adrenergic receptor agonists | ALLERGAN, INC. (US) | 2016-03-22 | — | — | US | disclosed |
| US-9289420-B2 | Method of activating regulatory T cells with alpha-2B adrenergic receptor agonists | ALLERGAN, INC. (US) | 2016-03-22 | — | — | US | disclosed |
| EP-2932968-A1 | COMPOUND FOR TREATING ALPHA ADRENERGIC MEDIATED CONDITIONS | ALLERGAN, INC. (US) | 2015-10-21 | — | — | EP | disclosed |
| EP-2932968-A1 | COMPOUND FOR TREATING ALPHA ADRENERGIC MEDIATED CONDITIONS | ALLERGAN, INC. (US) | 2015-10-21 | — | — | EP | disclosed |
| US-20150224080-A1 | METHODS OF TREATING ALPHA ADRENERGIC MEDIATED CONDITIONS | ALLERGAN, INC. | 2015-08-13 | — | — | US | disclosed |
| US-20150224080-A1 | METHODS OF TREATING ALPHA ADRENERGIC MEDIATED CONDITIONS | ALLERGAN, INC. | 2015-08-13 | — | — | US | disclosed |
| US-20150224080-A1 | METHODS OF TREATING ALPHA ADRENERGIC MEDIATED CONDITIONS | ALLERGAN, INC. | 2015-08-13 | — | — | US | disclosed |
| US-9034910-B2 | Methods of treating alpha adrenergic mediated conditions | ALLERGAN, INC. (US) | 2015-05-19 | — | — | US | disclosed |
| US-9034910-B2 | Methods of treating alpha adrenergic mediated conditions | ALLERGAN, INC. (US) | 2015-05-19 | — | — | US | disclosed |
| US-9034910-B2 | Methods of treating alpha adrenergic mediated conditions | ALLERGAN, INC. (US) | 2015-05-19 | — | — | US | disclosed |
| CN-102099032-B | Methods of treating alpha adrenergic mediated conditions | ALLERGAN INC | 2014-07-09 | — | — | CN | disclosed |
| US-20140066483-A1 | METHOD OF ACTIVATING REGULATORY T CELLS WITH ALPHA-2B ADRENERGIC RECEPTOR AGONISTS | ALLERGAN, INC. (US) | 2014-03-06 | — | — | US | disclosed |
| US-20140066483-A1 | METHOD OF ACTIVATING REGULATORY T CELLS WITH ALPHA-2B ADRENERGIC RECEPTOR AGONISTS | ALLERGAN, INC. (US) | 2014-03-06 | — | — | US | disclosed |
| US-8575207-B2 | Method of activating regulatory T cells with alpha-2B adrenergic receptor agonists | ALLERGAN, INC. (US) | 2013-11-05 | — | — | US | disclosed |
| US-8575207-B2 | Method of activating regulatory T cells with alpha-2B adrenergic receptor agonists | ALLERGAN, INC. (US) | 2013-11-05 | — | — | US | disclosed |
| WO-2013074320-A1 | ALPHA-2B RECEPTOR AGONIST AND ANTICONVULSANT COMPOSITIONS FOR TREATING CHRONIC PAIN | ALLERGAN, INC. (US) | 2013-05-23 | — | — | WO | disclosed |
| US-20120190719-A1 | METHODS OF TREATING MOTOR DISORDERS WITH ALPHA-2B ANDRENERGIC RECEPTOR AGONISTS | ALLERGAN, INC. (US) | 2012-07-26 | — | — | US | disclosed |
| US-20120190719-A1 | METHODS OF TREATING MOTOR DISORDERS WITH ALPHA-2B ANDRENERGIC RECEPTOR AGONISTS | ALLERGAN, INC. (US) | 2012-07-26 | — | — | US | disclosed |
| US-20120165380-A1 | METHODS OF TREATING ALPHA ADRENERGIC MEDIATED CONDITIONS | ALLERGAN, INC. (US) | 2012-06-28 | — | — | US | disclosed |
| US-20120165380-A1 | METHODS OF TREATING ALPHA ADRENERGIC MEDIATED CONDITIONS | ALLERGAN, INC. (US) | 2012-06-28 | — | — | US | disclosed |
| US-20120165380-A1 | METHODS OF TREATING ALPHA ADRENERGIC MEDIATED CONDITIONS | ALLERGAN, INC. (US) | 2012-06-28 | — | — | US | disclosed |
| US-20120083508-A1 | ALPHA-2B RECEPTOR AGONIST AND ANTICONVULSANT COMPOSITIONS FOR TREATING CHRONIC PAIN | ALLERGAN, INC. (US) | 2012-04-05 | — | — | US | disclosed |
| US-20120083508-A1 | ALPHA-2B RECEPTOR AGONIST AND ANTICONVULSANT COMPOSITIONS FOR TREATING CHRONIC PAIN | ALLERGAN, INC. (US) | 2012-04-05 | — | — | US | disclosed |
| WO-2012024161-A1 | METHOD OF ACTIVATING REGULATORY T CELLS WITH ALPHA-2B ADRENERGIC RECEPTOR AGONISTS | ALLERGAN, INC. (US) | 2012-02-23 | — | — | WO | disclosed |
| US-20120041031-A1 | METHOD OF ACTIVATING REGULATORY T CELLS WITH ALPHA-2B ADRENERGIC RECEPTOR AGONISTS | ALLERGAN, INC (US) | 2012-02-16 | — | — | US | disclosed |
| US-20120041031-A1 | METHOD OF ACTIVATING REGULATORY T CELLS WITH ALPHA-2B ADRENERGIC RECEPTOR AGONISTS | ALLERGAN, INC (US) | 2012-02-16 | — | — | US | disclosed |
| US-20120035235-A1 | METHODS OF TREATING ALPHA ADRENERGIC MEDIATED CONDITIONS | ALLERGAN, INC. (US) | 2012-02-09 | — | — | US | disclosed |
| US-20120035235-A1 | METHODS OF TREATING ALPHA ADRENERGIC MEDIATED CONDITIONS | ALLERGAN, INC. (US) | 2012-02-09 | — | — | US | disclosed |
| US-20120035235-A1 | METHODS OF TREATING ALPHA ADRENERGIC MEDIATED CONDITIONS | ALLERGAN, INC. (US) | 2012-02-09 | — | — | US | disclosed |
| US-8071636-B2 | Methods of treating alpha adrenergic mediated conditions | ALLERGAN, INC. (US) | 2011-12-06 | — | — | US | disclosed |
| US-8071636-B2 | Methods of treating alpha adrenergic mediated conditions | ALLERGAN, INC. (US) | 2011-12-06 | — | — | US | disclosed |
| US-8071636-B2 | Methods of treating alpha adrenergic mediated conditions | ALLERGAN, INC. (US) | 2011-12-06 | — | — | US | disclosed |
| US-8063231-B2 | Methods of treating alpha adrenergic mediated conditions | ALLERGAN, INC. (US) | 2011-11-22 | — | — | US | disclosed |
| US-8063231-B2 | Methods of treating alpha adrenergic mediated conditions | ALLERGAN, INC. (US) | 2011-11-22 | — | — | US | disclosed |
| US-8063231-B2 | Methods of treating alpha adrenergic mediated conditions | ALLERGAN, INC. (US) | 2011-11-22 | — | — | US | disclosed |
| EP-2377534-A1 | Methods of treating alpha adrenergic mediated conditions | ALLERGAN, INC. (US) | 2011-10-19 | — | — | EP | disclosed |
| EP-2377534-A1 | Methods of treating alpha adrenergic mediated conditions | ALLERGAN, INC. (US) | 2011-10-19 | — | — | EP | disclosed |
| US-20110160265-A1 | METHOD OF TREATING MOTOR DISORDERS WITH ALPHA-2B ADRENERGIC RECEPTOR AGONISTS | LUHRS LAUREN M B | 2011-06-30 | — | — | US | disclosed |
| US-20110160265-A1 | METHOD OF TREATING MOTOR DISORDERS WITH ALPHA-2B ADRENERGIC RECEPTOR AGONISTS | LUHRS LAUREN M B | 2011-06-30 | — | — | US | disclosed |
| EP-2303264-A1 | METHODS OF TREATING ALPHA ADRENERGIC MEDIATED CONDITIONS | Allergan, Inc. (US) | 2011-04-06 | — | — | EP | disclosed |
| WO-2009152053-A1 | METHODS OF TREATING ALPHA ADRENERGIC MEDIATED CONDITIONS USING IMIDAZOLINE DERIVATES | ALLERGAN, INC. (US) | 2009-12-17 | — | — | WO | disclosed |
| WO-2009152053-A1 | METHODS OF TREATING ALPHA ADRENERGIC MEDIATED CONDITIONS USING IMIDAZOLINE DERIVATES | ALLERGAN, INC. (US) | 2009-12-17 | — | — | WO | disclosed |
| WO-2009152052-A1 | METHODS OF TREATING ALPHA ADRENERGIC MEDIATED CONDITIONS | ALLERGAN, INC. (US) | 2009-12-17 | — | — | WO | disclosed |
| WO-2009152052-A1 | METHODS OF TREATING ALPHA ADRENERGIC MEDIATED CONDITIONS | ALLERGAN, INC. (US) | 2009-12-17 | — | — | WO | disclosed |
| US-20090306161-A1 | METHODS OF TREATING ALPHA ADRENERGIC MEDIATED CONDITIONS | ALLERGAN, INC. (US) | 2009-12-10 | — | — | US | disclosed |
| US-20090306161-A1 | METHODS OF TREATING ALPHA ADRENERGIC MEDIATED CONDITIONS | ALLERGAN, INC. (US) | 2009-12-10 | — | — | US | disclosed |
| US-20090306161-A1 | METHODS OF TREATING ALPHA ADRENERGIC MEDIATED CONDITIONS | ALLERGAN, INC. (US) | 2009-12-10 | — | — | US | disclosed |
| US-20090306398-A1 | METHODS OF TREATING ALPHA ADRENERGIC MEDIATED CONDITIONS | ALLERGAN, INC. (US) | 2009-12-10 | — | — | US | disclosed |
| US-20090306398-A1 | METHODS OF TREATING ALPHA ADRENERGIC MEDIATED CONDITIONS | ALLERGAN, INC. (US) | 2009-12-10 | — | — | US | disclosed |
| US-20090306398-A1 | METHODS OF TREATING ALPHA ADRENERGIC MEDIATED CONDITIONS | ALLERGAN, INC. (US) | 2009-12-10 | — | — | US | disclosed |
| WO-2009052075-A2 | METHOD OF TREATING MOTOR DISORDERS WITH ALPHA-2B ADRENERGIC RECEPTOR AGONISTS | ALLERGAN, INC. (US) | 2009-04-23 | — | — | WO | disclosed |
| WO-2009052075-A2 | METHOD OF TREATING MOTOR DISORDERS WITH ALPHA-2B ADRENERGIC RECEPTOR AGONISTS | ALLERGAN, INC. (US) | 2009-04-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (19 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120041031-A1 | METHOD OF ACTIVATING REGULATORY T CELLS WITH ALPHA-2B ADRENERGIC RECEPTOR AGONISTS | ADRA2B, ADRB2, ADRA2A | ADRA2A 3/4885LMNA 2965/4885ADRA2B 1/4885 |
| US-20180071259-A1 | METHOD OF ACTIVATING REGULATORY T CELLS WITH ALPHA-2B ADRENERGIC RECEPTOR AGONISTS | ADRA2B, ADRB2, ADRA2A | ADRA2A 3/4885LMNA 2921/4885ADRA2B 1/4885 |
| US-20090306161-A1 | METHODS OF TREATING ALPHA ADRENERGIC MEDIATED CONDITIONS | ADRB2, ADRA2C, ADRA2A | ADRA2A 3/4885LMNA 1467/4885ADRA2B 7/4885 |
| US-20230062049-A1 | METHODS OF TREATING ALPHA ADRENERGIC MEDIATED CONDITIONS | ADRB2, ADRA2A, ADRA2C | ADRA2A 2/4885LMNA 1464/4885ADRA2B 7/4885 |
| US-20150224080-A1 | METHODS OF TREATING ALPHA ADRENERGIC MEDIATED CONDITIONS | ADRB2, ADRA2A, ADRA2C | ADRA2A 2/4885LMNA 1464/4885ADRA2B 7/4885 |
| US-20140066483-A1 | METHOD OF ACTIVATING REGULATORY T CELLS WITH ALPHA-2B ADRENERGIC RECEPTOR AGONISTS | ADRA2B, ADRB2, ADRA2A | ADRA2A 3/4885LMNA 2965/4885ADRA2B 1/4885 |
| US-20090306398-A1 | METHODS OF TREATING ALPHA ADRENERGIC MEDIATED CONDITIONS | ADRB2, ADRA2C, ADRA2A | ADRA2A 3/4885LMNA 1467/4885ADRA2B 7/4885 |
| US-20120035235-A1 | METHODS OF TREATING ALPHA ADRENERGIC MEDIATED CONDITIONS | ADRB2, ADRA2C, ADRA2A | ADRA2A 3/4885LMNA 1467/4885ADRA2B 7/4885 |
| US-20110160265-A1 | METHOD OF TREATING MOTOR DISORDERS WITH ALPHA-2B ADRENERGIC RECEPTOR AGONISTS | ADRA2B, ADRA2A, ADRA2C | ADRA2A 2/4885LMNA 1651/4885ADRA2B 1/4885 |
| US-20160158199-A1 | METHOD OF ACTIVATING REGULATORY T CELLS WITH ALPHA-2B ADRENERGIC RECEPTOR AGONISTS | ADRA2B, ADRB2, ADRA2A | ADRA2A 3/4885LMNA 2921/4885ADRA2B 1/4885 |
| US-20120083508-A1 | ALPHA-2B RECEPTOR AGONIST AND ANTICONVULSANT COMPOSITIONS FOR TREATING CHRONIC PAIN | CNR2, OPRL1, OPRD1 | ADRA2A 39/4885LMNA 3481/4885ADRA2B 6/4885 |
| US-20170172982-A1 | METHODS OF TREATING ALPHA ADRENERGIC MEDIATED CONDITIONS | ADRB2, ADRA2A, ADRA2C | ADRA2A 2/4885LMNA 1464/4885ADRA2B 7/4885 |
| US-20180071260-A1 | METHODS OF TREATING ALPHA ADRENERGIC MEDIATED CONDITIONS | ADRB2, ADRA2A, ADRA2C | ADRA2A 2/4885LMNA 1464/4885ADRA2B 7/4885 |
| US-20200330428-A1 | METHODS OF TREATING ALPHA ADRENERGIC MEDIATED CONDITIONS | ADRB2, ADRA2A, ADRA2C | ADRA2A 2/4885LMNA 1464/4885ADRA2B 7/4885 |
| US-20170079956-A1 | METHOD OF ACTIVATING REGULATORY T CELLS WITH ALPHA-2B ADRENERGIC RECEPTOR AGONISTS | ADRA2B, ADRB2, ADRA2A | ADRA2A 3/4885LMNA 2914/4885ADRA2B 1/4885 |
| US-10251865-B2 | Method of activating regulatory T cells with alpha-2B adrenergic receptor agonists | ADRA2B, ADRB2, ADRA2A | ADRA2A 3/4885LMNA 2921/4885ADRA2B 1/4885 |
| US-20180344692-A1 | METHODS OF TREATING ALPHA ADRENERGIC MEDIATED CONDITIONS | ADRB2, ADRA2A, ADRA2C | ADRA2A 2/4885LMNA 1464/4885ADRA2B 7/4885 |
| US-20120190719-A1 | METHODS OF TREATING MOTOR DISORDERS WITH ALPHA-2B ANDRENERGIC RECEPTOR AGONISTS | CHRNB2, HTR2B, CHRNA2 | ADRA2A 22/4885LMNA 3609/4885ADRA2B 20/4885 |
| US-20120165380-A1 | METHODS OF TREATING ALPHA ADRENERGIC MEDIATED CONDITIONS | ADRB2, ADRA2A, ADRA2C | ADRA2A 2/4885LMNA 1464/4885ADRA2B 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.